San Raffaele Hospital

Athenex Taps NCI TCRs For Solid Tumor Off-The-Shelf Therapy Athenex, Inc. announced a licensing agreement on 9 November with the US National Cancer Institute (NCI) to expand its development capabil

Gene therapies that program the body to make therapeutic antibodies, genetic surgery that replaces anatomical surgery and cell therapies designed to attack individual cancer patients’ tumors almost so

April has been an astonishing month for biopharmaceutical venture capital investment, with billions of dollars in new financings and new VC funds. About $1bn in new venture rounds were announced durin

The second quarter was a record-breaking period with China-focused biopharma start-ups and others raising hundreds of millions of dollars in venture capital. Both the amount of money raised and the nu